We use mass spectrometry-based proteomics to study signal transduction in disease, with a focus on the NRF2 pathway and ‘dark’ kinases. Ongoing projects include the cryoEM structure of KEAP1/NRF2, cell biology of KEAP1 mutations and biomolecular condensates, and small molecule screens for NRF2 inhibitors, including novel compounds that block one-carbon metabolism. We also study NRF2 in new mouse models of cancer and across clinical tumor biopsies using targeted proteomics. We lead a new clinical trial for a NRF2 inhibitor in head and neck cancer. Understudied kinases are being illuminated through large scale promiscuous biotin proximity proteomics and computational scoring.
Research keywords: proteomics; cancer; signal transduction
Basic information
| Pronouns: | He/Him/His |
| Mentoring statement: | Find it here. |
| Some former postdocs’ career outcomes: | Chase Weidmann….assist professor at U of Michigan Dennis Goldfarb…..assist professor at WashU Travis Schrank….assist professor at UNC-Chapel Hill Kathleen Mulvaney… assist professor at Virginia Tech Feng Yan…….director at IMMORNA Matt Walker….senior principle scientist at Element Genomics |
Postdoc openings within the next year
| Number of postdoc positions: | 1 |
| Postdoc eligibility: | U.S. Citizens or Permanent Residents Current Visa-Holding Trainees in the U.S. International Trainees Outside the U.S. |